DUBLIN--(BUSINESS WIRE)--The "Global Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global kidney cancer/renal cell carcinoma drugs market was valued at US$ 3,302.3 million in 2016, and is expected to reach US$ 6,441.9 million by 2025, expanding at a CAGR of 8.1% from 2017 to 2025
Kidney cancer/renal cell carcinoma (RCC) is the sixth most common cancer observed in men and it is the tenth most common cause of cancer for women. Around 63,990 new cases of kidney cancer will be diagnosed (40,610 men and 23,380 women). The average age of diagnosis is 64 and is rarely found in people under 45. It is estimated that 65% of people are diagnosed when the cancer is only located in the kidney and the 5-year survival rate is 93% in this group.
The incidence of renal cell cancer is observed highest in Northern America and Europe. Almost 59% of kidney cancer cases is observed in developed countries. Thus, rising incidence of kidney cancer and entry of novel drug treatment are the key factors contributing to the growth of kidney cancer drug market.
Sutent dominates the global kidney cancer/renal cell carcinoma drugs market.
North America dominates the global kidney cancer drugs market followed by Europe. Rise in incidence of renal cancer, increasing geriatric population and novel drug treatment are key drivers for the growth of kidney cancer drug market in North America.
Asia Pacific is the fastest growing regional market for kidney cancer drugs with highest CAGR in the forecast period. With improvement in diagnostic technology, rise in aged population and low cost production of drugs are some of the key factors contributing to the growth of Asia Pacific region.
Key Topics Covered:
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Kidney Cancer Drugs: Market Dynamics and Future Outlook
Chapter 4. Global Kidney Cancer Drugs Market, by Type, 2015-2025 (US$ Mn)
Chapter 5. Global Kidney Cancer Drugs Market: Pipeline Analysis
Chapter 6. Global Kidney Cancer Drugs Market, by Geography, 2015-2025 (US$ Mn)
Chapter 7. Company Profiles
- Active Biotech Ab
- Bayer AG
- Cipla Limited
- F. Hoffmann-La Roche Ag
- Genentech, Inc.
- Glaxosmithkline Plc
- Novartis Ag
- Pfizer, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/vz7t5h/global_kidney?w=4